Search Results - "Javle, Milind M"

Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation by Krishnan, Sunil, MD, Chadha, Awalpreet S., MD, Suh, Yelin, PhD, Chen, Hsiang-Chun, PhD, Rao, Arvind, PhD, Das, Prajnan, MD, Minsky, Bruce D., MD, Mahmood, Usama, MD, Delclos, Marc E., MD, Sawakuchi, Gabriel O., PhD, Beddar, Sam, PhD, Katz, Matthew H., MD, Fleming, Jason B., MD, Javle, Milind M., MD, Varadhachary, Gauri R., MD, Wolff, Robert A., MD, Crane, Christopher H., MD

“…Purpose To review outcomes of locally advanced pancreatic cancer (LAPC) patients treated with dose-escalated intensity modulated radiation therapy (IMRT) with…”
Get full text

Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline by Balaban, Edward P, Mangu, Pamela B, Khorana, Alok A, Shah, Manish A, Mukherjee, Somnath, Crane, Christopher H, Javle, Milind M, Eads, Jennifer R, Allen, Peter, Ko, Andrew H, Engebretson, Anitra, Herman, Joseph M, Strickler, John H, Benson, 3rd, Al B, Urba, Susan, Yee, Nelson S

“…To provide evidence-based recommendations to oncologists and others for treatment of patients with locally advanced, unresectable pancreatic cancer. American…”
Get full text

Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of Smad4(Dpc4) Immunostaining With Pattern of Disease Progression by CRANE, Christopher H, VARADHACHARY, Gauri R, DAS, Prajnan, LEE, Jeffrey E, ABBRUZZESE, James L, WOLFF, Robert A, YORDY, John S, STAERKEL, Gregg A, JAVLE, Milind M, SAFRAN, Howard, HAQUE, Waqar, HOBBS, Bridgett D, KRISHNAN, Sunil, FLEMING, Jason B

“…This phase II trial was designed to assess the efficacy and safety of cetuximab, gemcitabine, and oxaliplatin followed by cetuximab, capecitabine, and…”
Get full text

Intrahepatic cholangiocarcinoma: The role of liver transplantation, adjunctive treatments, and prognostic biomarkers by Connor, Ashton A, Kodali, Sudha, Abdelrahim, Maen, Javle, Milind M, Brombosz, Elizabeth W, Ghobrial, R Mark

“…Intrahepatic cholangiocarcinoma (iCCA) is a primary epithelial cell malignancy of the liver with rising incidence rate globally. Its insidious presentation,…”
Get full text

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies by Javle, Milind M, Shroff, Rachna T, Xiong, Henry, Varadhachary, Gauri A, Fogelman, David, Reddy, Shrikanth A, Davis, Darren, Zhang, Yujian, Wolff, Robert A, Abbruzzese, James L

“…The phosphoinositide 3-kinase (PI3K)/Akt pathway is constitutively activated in pancreatic cancer and the mammalian target of rapamycin (mTOR) kinase is an…”
Get full text

Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma by Chadha, Awalpreet S., Gunther, Jillian R., Hsieh, Cheng-En, Aliru, Maureen, Mahadevan, Lakshmi S., Venkatesulu, Bhanu P., Crane, Christopher H., Das, Prajnan, Herman, Joseph M., Koay, Eugene J., Taniguchi, Cullen, Holliday, Emma B., Minsky, Bruce D., Suh, Yelin, Park, Peter, Sawakuchi, Gabriel, Beddar, Sam, Odisio, Bruno C., Gupta, Sanjay, Loyer, Evelyne, Kaur, Harmeet, Raghav, Kanwal, Javle, Milind M., Kaseb, Ahmed O., Krishnan, Sunil

“…•Escalating radiation dose to hepatocellular carcinoma (HCC) using protons is feasible.•Moderate-to-large unresectable tumors in a Western cohort of…”
Get full text

Nuclear or cytoplasmic expression of survivin: What is the significance? by Li, Fengzhi, Yang, Jie, Ramnath, Nithya, Javle, Milind M., Tan, Dongfeng

“…Growing evidence suggests that survivin expression in cancer cell nuclei may represent an important prognostic marker to predict disease outcome for cancer…”
Get full text

Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients by Mohindroo, Chirayu, Hasanov, Merve, Rogers, Jane E., Dong, Wenli, Prakash, Laura R., Baydogan, Seyda, Mizrahi, Jonathan D., Overman, Michael J., Varadhachary, Gauri R., Wolff, Robert A., Javle, Milind M., Fogelman, David R., Lotze, Michael T., Kim, Michael P., Katz, Matthew H.G., Pant, Shubham, Tzeng, Ching‐Wei D., McAllister, Florencia

“…Recent studies defined a potentially important role of the microbiome in modulating pancreatic ductal adenocarcinoma (PDAC) and responses to therapies. We…”
Get full text

Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer by Chadha, Awalpreet S, Skinner, Heath D, Gunther, Jillian R, Munsell, Mark F, Das, Prajnan, Minsky, Bruce D, Delclos, Marc E, Chatterjee, Deyali, Wang, Huamin, Clemons, Marilyn, George, Geena, Singh, Pankaj K, Katz, Matthew H, Fleming, Jason B, Javle, Milind M, Wolff, Robert A, Varadhachary, Gauri R, Crane, Christopher H, Krishnan, Sunil

“…To determine the safety, tolerability and maximum tolerated dose (MTD) of addition of erlotinib to bevacizumab and capecitabine-based definitive chemoradiation…”
Get full text

Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma by Chadha, Krishdeep S, Khoury, Thaer, Yu, Jihnhee, Black, Jennifer D, Gibbs, John F, Kuvshinoff, Boris W, Tan, Dongfeng, Brattain, Michael G, Javle, Milind M

“…Long-term survival of surgically resectable pancreatic cancer patients is uncommon. The epidermal growth factor receptor (EGFR) and the…”
Get full text

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma by Rogers, Jane E., Mizrahi, Jonathan D., Xiao, Lianchun, Mohindroo, Chirayu, Shroff, Rachna T., Wolff, Robert, Varadhachary, Gauri R., Javle, Milind M., Overman, Michael, Fogelman, David R., Raghav, Kanwal P. S., Pant, Shubham, McAllister, Florencia

“…Background Gemcitabine (GEM) plus nab‐paclitaxel (NabP) (GEM 1000 mg/m2 IV over 30 minutes + NabP 125 mg/m2 IV given days 1, 8, and 15 every 28 days) is one of…”
Get full text

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study by Abou-Alfa, Ghassan K, Macarulla, Teresa, Javle, Milind M, Kelley, Robin K, Lubner, Sam J, Adeva, Jorge, Cleary, James M, Catenacci, Daniel V, Borad, Mitesh J, Bridgewater, John, Harris, William P, Murphy, Adrian G, Oh, Do-Youn, Whisenant, Jonathan, Lowery, Maeve A, Goyal, Lipika, Shroff, Rachna T, El-Khoueiry, Anthony B, Fan, Bin, Wu, Bin, Chamberlain, Christina X, Jiang, Liewen, Gliser, Camelia, Pandya, Shuchi S, Valle, Juan W, Zhu, Andrew X

“…Isocitrate dehydrogenase 1 (IDH1) mutations occur in approximately 13% of patients with intrahepatic cholangiocarcinoma, a relatively uncommon cancer with a…”
Get full text

A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer by El-Rayes, Bassel Fuad, Philip, Philip A., Sarkar, Fazlul H., Shields, Anthony F., Ferris, Ann Marie, Hess, Kenneth, Kaseb, Ahmad O., Javle, Milind M., Varadhachary, Gauri R., Wolff, Robert A., Abbruzzese, James L.

“…Summary Background : The EGFR/Akt/NF-κB signalling pathway is frequently deregulated in pancreatic cancer and contributes to cell growth, metastasis and…”
Get full text

Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers by Singhi, Aatur D., George, Ben, Greenbowe, Joel R., Chung, Jon, Suh, James, Maitra, Anirban, Klempner, Samuel J., Hendifar, Andrew, Milind, Javle M., Golan, Talia, Brand, Randall E., Zureikat, Amer H., Roy, Somak, Schrock, Alexa B., Miller, Vincent A., Ross, Jeffrey S., Ali, Siraj M., Bahary, Nathan

“…It has been a challenge to select treatment for patients with pancreatic ductal adenocarcinomas (PDACs) based on genome alterations. We performed targeted…”
Get full text

A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study by Iyer, Renuka V, Gibbs, John, Kuvshinoff, Boris, Fakih, Marwan, Kepner, James, Soehnlein, Nancy, Lawrence, David, Javle, Milind M

“…To determine the clinical benefit response (CBR), time to tumor progression (TTP), overall survival, and effect on quality of life (QOL) of gemcitabine and…”
Get full text

High-dose Octreotide Acetate for Management of Gastroenteropancreatic Neuroendocrine Tumors by CHADHA, Manpreet K, LOMBARDO, Jeffrey, MASHTARE, Terry, WILDING, Gregory E, LITWIN, Alan, RACZYK, Cheryl, GIBBS, John F, KUVSHINOFF, Boris, JAVLE, Milind M, IYER, Renuka V

“…Background: Long-acting sandostatin (S-LAR; octreotide acetate) is well tolerated and effective for symptom control and possibly disease control in…”
Get full text

Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial by Shroff, Rachna T, Javle, Milind M, Xiao, Lianchun, Kaseb, Ahmed O, Varadhachary, Gauri R, Wolff, Robert A, Raghav, Kanwal P S, Iwasaki, Michiko, Masci, Peter, Ramanathan, Ramesh K, Ahn, Daniel H, Bekaii-Saab, Tanios S, Borad, Mitesh J

“…Administration of gemcitabine-cisplatin, the current standard therapy for advanced biliary tract cancers, results in median progression-free survival and…”
Get more information

Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis by Tao, Randa, Krishnan, Sunil, Bhosale, Priya R, Javle, Milind M, Aloia, Thomas A, Shroff, Rachna T, Kaseb, Ahmed O, Bishop, Andrew J, Swanick, Cameron W, Koay, Eugene J, Thames, Howard D, Hong, Theodore S, Das, Prajnan, Crane, Christopher H

“…Standard therapies for localized inoperable intrahepatic cholangiocarcinoma (IHCC) are ineffective. Advances in radiotherapy (RT) techniques and image guidance…”
Get full text

Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma by Hong, Theodore S, Wo, Jennifer Y, Yeap, Beow Y, Ben-Josef, Edgar, McDonnell, Erin I, Blaszkowsky, Lawrence S, Kwak, Eunice L, Allen, Jill N, Clark, Jeffrey W, Goyal, Lipika, Murphy, Janet E, Javle, Milind M, Wolfgang, John A, Drapek, Lorraine C, Arellano, Ronald S, Mamon, Harvey J, Mullen, John T, Yoon, Sam S, Tanabe, Kenneth K, Ferrone, Cristina R, Ryan, David P, DeLaney, Thomas F, Crane, Christopher H, Zhu, Andrew X

“…To evaluate the efficacy and safety of high-dose, hypofractionated proton beam therapy for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma…”
Get full text

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial by Zhu, Andrew X, Macarulla, Teresa, Javle, Milind M, Kelley, R Kate, Lubner, Sam J, Adeva, Jorge, Cleary, James M, Catenacci, Daniel V T, Borad, Mitesh J, Bridgewater, John A, Harris, William P, Murphy, Adrian G, Oh, Do-Youn, Whisenant, Jonathan R, Lowery, Maeve A, Goyal, Lipika, Shroff, Rachna T, El-Khoueiry, Anthony B, Chamberlain, Christina X, Aguado-Fraile, Elia, Choe, Sung, Wu, Bin, Liu, Hua, Gliser, Camelia, Pandya, Shuchi S, Valle, Juan W, Abou-Alfa, Ghassan K

“…Isocitrate dehydrogenase 1 (IDH1) variations occur in up to approximately 20% of patients with intrahepatic cholangiocarcinoma. In the ClarIDHy trial,…”
Get more information